Latest Headlines

  1. Nona Biosciences And Pfizer Announce Strategic Research Collaboration To Accelerate Antibody Discovery 11/19/2025

    Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.

  2. Emulate Launches Brain-Chip R1 To Advance Neurological Drug Development, In Partnership With FUJIFILM Cellular Dynamics 11/18/2025

    Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, in partnership with FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announced the launch of the Emulate Brain-Chip R1.

  3. DiaGen AI Inc. And Metanova Labs Announce Joint Venture LOI To Develop Hit Picking Tool For Automating Drug Discovery 11/18/2025

    DiaGen AI Inc. (“DiaGen”, or the Company) founded in 2021, established to advance a diverse pipeline of AI drug discovery tools to scale its asset development and provide solutions through its Ai aS A Partner offering to impact traditional drug discovery, is pleased to announce a milestone driven joint venture LOI (the "JV") with Metanova Labs ("Metanova"), pioneers of crypto-native drug discovery with the world’s first decentralized virtual drug screening platform, NOVA, built on the Bittensor network.

  4. BioDuro Launches Dedicated Peptide Business Unit, Accelerating Integrated Drug Discovery Solutions 11/18/2025

    BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners, underscoring the company's commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.

  5. GSK And Fleming Initiative Scientists Unite To Target AMR With Advanced AI 11/18/2025

    GSK and the Fleming Initiative today announced six major new research programmes, called ‘Grand Challenges’ which harness some of the best scientific expertise and the latest technologies, including advanced AI, to find new ways to slow the progress of antimicrobial resistance (AMR).

  6. Onco-Innovations Advances AI And Quantum Drug Discovery With Kuano Collaboration To Accelerate PNKP Inhibitor Technology Development 11/18/2025

    Onco-Innovations Limited ("Onco" or the "Company”) is pleased to announce that it is initiating a pilot project with Kuano Ltd. (Kuano) to accelerate development of Onco’s PNKP Inhibitor Technology (also known as A83B4C63).

  7. Terray Announces EMMI, An AI-Native Drug Discovery Platform For de Novo Small Molecule Drug Discovery 11/17/2025

    Terray Therapeutics, an AI-native, chemistry-first, biotech today announced its AI and experimental platform, EMMI, and the introduction of advanced Select models that choose the most impactful molecules to make and test in every cycle of drug discovery.

  8. EMA Positive Opinion For Orphan Drug Designation To BioInvent's BI 1808 For The Treatment Of Cutaneous T-cell Lymphoma 11/17/2025

    BioInvent International AB (“BioInvent”), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has adopted a positive opinion for Orphan Drug Designation (ODD) to the company’s investigational medicinal product BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of Cutaneous T-cell Lymphoma (CTCL).

  9. Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For SPC-15 As A Therapeutic For PTSD 11/17/2025

    Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company’s final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD.

  10. Celcuity Announces Completion Of Submission Of Its New Drug Application To The U.S. FDA For Gedatolisib In HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer 11/17/2025

    Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), advanced breast cancer (“ABC”).